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Aims: The RELAX-OAB study is designed to confirm the safety, efficacy, and
technical performance of the Axonics r-SNM System, a miniaturized, rechargeable
SNM system approved in Europe and Canada for the treatment of bladder and bowel
dysfunction. The purpose of this article is to describe study subjects’ ability to charge
the rechargeable neurostimulator and to document their neurostimulator program
settings and recharge interval over time.
Methods: Fifty-one OAB patients were implanted in a single-stage procedure.
These results represent the 3-month charging experience for 48 subjects who
completed the 3-month follow-up. Recharge intervals were estimated using therapy
stimulation settings and subject experience was evaluated using questionnaires.
Results: Forty-seven of forty-eight (98%) subjects were able to successfully
charge their device prior to follow-up within 1-month post-implant. At 3-month
post-implant, 98% of subjects were able to charge prior to their follow-up visit.
Average stimulation amplitude across all subjects was 1.8 mA (±1.1 mA). A total
of 69% of subjects had ≥14-day recharge intervals (time between charging) and
98% of subjects had≥7-day recharge interval. No charging related adverse events
occurred.
Conclusions: Study subjects were able to charge the Axonics r-SNM System and
stimulation settings provided 2 weeks of therapy between recharging for most
subjects. Subject satisfaction indicates that subjects are satisfied with rechargeable
SNM therapy.
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1 | INTRODUCTION
Over 250 000 patients with bladder and bowel dysfunction
have been treated with sacral neuromodulation (SNM) over
the past 20 years.1 For these patients, the only commercialized
SNM treatment option was a non-rechargeable SNM system
that is replaced every 3-5 years when the neurostimulator
battery depletes. System replacement procedures are burden-
some to patients and physicians and are associated with
surgical risk to the patient, including risk of infection and loss
of efficacy. SNM practices and technology have evolved over
time, most notably with the introduction of the tined lead and
percutaneous implant procedure in the early 2000s. Studies
have shown that the improved technology and techniques
have increased therapy efficacy and decreased surgical
revision and explant rates.2–4
Despite the improvements in some aspects of SNM, the
therapy has lacked the technological innovation seen in other
areas of neuromodulation, namely spinal cord stimulation
(SCS) and deep brain stimulation (DBS). Rechargeable
neuromodulation systems lasting 10 or more years in the body
were introduced for SCS in 2006,5 but were not available for
SNM until recently. In 2016, the Axonics r-SNM System™, a
miniaturized, rechargeable SNM system, obtained regulatory
approval in Europe and Canada. The system is designed and
tested to deliver therapy in the body for a minimum of
15 years and includes an implantable neurostimulator that is
5 cc in volume, a 60% reduction in size compared to the 14 cc
Interstim II (Medtronic, Minneapolis, MN). An independent,
expert review provides additional detail about SNM therapy
and the characteristics and specifications of the Axonics
r-SNM System.6
The RELAX-OAB study is a prospective, multi-center
post-market clinical follow-up study designed with the
primary aim of confirming the safety and technical perfor-
mance of the Axonics r-SNM System. The aim of this study is
to describe the usability and subject satisfaction with the
rechargeable neurostimulator and document the study sub-
jects’ neurostimulator program settings and recharge interval
based on the first 3 months of the RELAX-OAB study.
2 | MATERIALS AND METHODS
2.1 | Study design
The RELAX-OAB study is a prospective, multi-center,
single arm, open-label study with each subject serving as
their own control. The study is being conducted according
to the stipulations of the Declaration of Helsinki, ISO
14155: 2011 and applicable national regulations. The study
protocol was approved by Ethics Committees at all study
sites, and all subjects gave informed consent prior to
participating in the study. Subjects were eligible for
treatment with the Axonics r-SNM System if they met all
inclusion and exclusion criteria. Additional study details
were previously reported.7
2.2 | Rechargeable SNM system
The Axonics r-SNM System (Figure 1) is a miniaturized,
implantable rechargeable SNM (r-SNM) system designed and
tested to deliver therapy in the body for at least 15 years.
The Axonics r-SNM System includes an implantable
neurostimulator that is 5 cc in volume, which is over 60%
smaller than the 14 cc Interstim II. The neurostimulator
connects to a 4-contact tined lead that is implanted through
the sacral foramen using the same procedure previously
described for other SNM systems.8 The system delivers
constant current stimulation and provides adjustable
stimulation parameters appropriate for SNM therapy.
Implanted patients recharge their neurostimulator, ex-
pected to be needed once every 2 weeks, using an external
charging unit placed over the implant. Stimulation
parameters are programmed with a clinician programmer
and stimulation intensity is controlled by the patient using
a wireless remote control. An independent, expert review
provides additional detail about SNM therapy and the
characteristics and specifications of the Axonics r-SNM
System.6
2.3 | Follow-up visits
Subjects were seen for follow-up visits at various time points
up to 1-year post-implant, including 2-week and 1-month
visits to assess initial response to therapy. Unscheduled
follow-up visits were allowed as needed to adjust stimulation
settings to optimize therapy. Data were collected on
stimulation therapy settings at each visit, and outcomes
were evaluated using a consecutive 3-day voiding diary, a
symptom-related quality of life (QOL) surveys (ICIQ-
OABqol, ICIQ-UI Short Form) and patient and physician
satisfaction questionnaires. Therapy Responders were de-
fined as subjects with a ≥50% improvement in their leaks or
voids, or a reduction to <8 voids per day, on their 3-day diary
at follow-up compared to baseline.
2.4 | Recharge interval
Estimates of the neurostimulator battery recharge interval
were provided by Axonics Modulation Technologies, Inc.,
the manufacturer of the Axonics r-SNM System. Recharge
interval estimates were based on active stimulation settings
when patients completed their 3-month visits, including the
stimulation amplitude, frequency, pulse width, and imped-
ance. The estimates of the recharge interval assume the
battery has been used for 15 years by utilizing factors that
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account for the effects on the battery capacity of aging and
repeated discharging and recharging equivalent to 15 years of
usage.
2.5 | Adverse events
All adverse events (AEs) were tracked and analyzed to assess
the safety of the Axonics r-SNM System. A Data Safety
Monitoring Board comprised of three expert clinicians not
participating as investigators in the study, reviewed and
adjudicated all adverse events.
3 | RESULTS
3.1 | Subject overview
Fifty-one subjects with OABwere implanted, and 48 subjects
had data available at 3-month post-implant. One patient was
explanted due to procedure-related infection and two subjects
were lost to follow-up. Seventy-five percent of subjects were
female and the average subject age was 51 ± 15 years (range:
21–77). Additional baseline subject characteristics, as well as
the efficacy and safety outcomes of this study, were reported
previously.7
3.2 | Stimulation settings
At implant and at 3 months all 48 subjects were programmed
to bipolar stimulation. Table 1 shows the average stimulation
settings across the subjects at each follow-up visit. Stimula-
tion amplitude increased from 1.1 ± 0.8 mA at implant to
1.7 ± 1.1 mA at 3 months, a 62% increase, however, most of
the increase occurred by 2 weeks post-implant at which point
the average amplitude was 1.5 ± 1.1 mA. Stimulation fre-
quency was 14 Hz for all subjects at implant and at 3 months
the average frequency was 14.3 ± 1.6 Hz showing minimal
change in stimulation frequency. Pulse width increased
nominally from 209.4 ± 4.3 μs at implant to 210.6 ± 11.6 μs
at 3 months. Impedance values decreased slightly from
implant (1005 ± 292Ω) to 2 weeks (946 ± 187Ω) and then
increased 27% on average to 1201 ± 214Ω at 3 months.
Cycling stimulation was not used for any subject.
Stimulation amplitude for the constant current recharge-
able neurostimulator is programmed based on the current
output (in mA). Stimulation amplitudes at 3 months ranged
from 0.4 to 5.8 mA. A total of 30 of 48 subjects (63%) had
stimulation amplitudes less than 2 mA and 90% had
amplitudes less than 3 mA (Figure 2).
3.3 | Estimated recharge interval
Stimulation settings were used to estimate the recharge
interval for the rechargeable neurostimulator. The method
to determine the recharge interval was developed and
provided by the manufacturer (Axonics Modulation Tech-
nologies, Inc., Irvine, CA). According to the manufacturer
the estimated recharge interval is based on extensive device
performance testing and represents the expected recharge
interval after 15 years of use.
Almost all subjects (98%) had at least a 7-day estimated
recharge interval, and 69% of subjects had estimated recharge
intervals >14 days (Figure 2). One subject had a 5-day
recharge interval with stimulation settings of 5.6 mA (or
7.6 V), 14 Hz frequency, and 210 μs pulse width.
3.4 | Ability to charge
At 3 months 98% of subjects charged their neurostimulator
without issue prior to their follow-up visit. A total of 96% of
subjects successfully charged as early as within 2 weeks of
implant. Subjects that were unable to charge at a follow-up
visit were retrained and all were able to charge on their own
prior to the next visit.
FIGURE 1 The Axonics r-SNM System includes a rechargeable,
miniaturized neurostimulator that is 5 cc in volume and has a 15-year
approved life in Europe and Canada
TABLE 1 Stimulation settings at follow-up visits
Stimulation Settings (mean± std dev)
Visit n Amplitude (mA) Frequency (Hz) Pulse width (μs) Impedance (Ohms)
Post-implant 51 1.1 ± 0.8 14 ± 0 209.4 ± 4.2 1005 ± 292
2 weeks 51 1.5 ± 1.1 14 ± 0 209.4 ± 4.2 946 ± 187
1 months 50 1.6 ± 1.1 13.9 ± 0.6 208.8 ± 6 964 ± 161
3 months 48 1.7 ± 1.1 14.3 ± 1.6 210.6 ± 11.6 1201 ± 214
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3.5 | Patient satisfaction
The majority of subjects reported satisfaction with their SNM
therapy at 3 months. Overall, 83% of implanted subjects were
satisfied with their therapy, and when analyzed for only
TherapyResponders the satisfaction rate rose to 94% (Figure 3).
Most Therapy Responders, 76%, were “Very Satisfied” with
r-SNM therapy. Despite not meeting the clinical criteria for
therapy success, 39% of Non-Responders were still “Very
Satisfied” with their therapy. Additionally, 100% of subjects
that responded to therapy reported theywere at least “Likely” to
recommend r-SNM therapy to a friend, and 88% said they
would “Definitely” recommend the therapy to a friend.
3.6 | Charging-related adverse events
Across all 51 implanted patients, no adverse events were
reported related to the recharging of the neurostimulator.
4 | DISCUSSION
Sacral neuromodulation has been proven to reduce symptoms
of bladder and bowel dysfunction and to improve patient
quality of life.2–4 New rechargeable SNM systems may
provide the ability to program patients, including utilizing
higher power settings, without the need to maximize battery
life associated with non-rechargeable SNM systems, which
can require sacrificing efficacy to extend battery life or
increasing programming visits to try advanced programming
options (eg, cycling stimulation). This study provides
evidence that subjects, particularly those experiencing
therapeutic benefit, are satisfied with rechargeable sacral
neuromodulation and recharging is neither a barrier for use
nor an unwanted burden.
These results provide the first report of stimulation settings
for subjects treated with a current-controlled, rechargeable
sacral neuromodulation system. Most of the stimulation
settings at 3-month post-implantwere similar to those reported
for the InSite trial, a 272-patient prospectivemulticenter study
using a voltage controlled system (Interstim II).9 Stimulation
frequency, pulse width, amplitude, and the associated
impedance values were relatively consistent over this
3-month follow-up period. Change in stimulation accounted
for the majority of any change in stimulation parameters
and most of this occurred during the first 2 weeks in what
would be considered an accommodation period. These
findings suggest that the programming approach and preferred
parameters are generally unchanged when programming this
current controlled rechargeable system compared to the
established practice for programming the voltage-controlled
non-rechargeable system. One major difference, however, is
that for this rechargeable system no patients had the cycling
feature turned on while 35% of subjects in the InSite study had
the cycling feature turned on at 3months. Several studies have
investigated the use of cycling as ameans to extend the battery
life of a non-rechargeable SNM system.10,11 However, a
rechargeable system may offer a simplified programming
process by reducing the use of cycling to extend battery life.
Further, a rechargeable systemmay reduce the trade-offsmade
during programming when trying to optimize both efficacy
and battery life. One subject in this study had a recharge
interval <7 days due to high stimulation amplitude (5.6 mA or
7.6 V), and this subject could potentially be reprogrammed in
the future with the cycling feature turned on to extend their
recharge interval.
Several studies have reported high rates of patient
satisfaction with rechargeable neuromodulation systems,12–15
including a strong preference for rechargeable systems in
patients that previously had non-rechargeable system.12–14
However, this is the first report describing patient experience
with a rechargeable SNM system. Patient preference and the
appropriateness of a rechargeable system versus a non-
rechargeable system may depend on a number of factors. A
larger cohort is necessary to determine if there are predictive
factors forwhether a patient is better suited for a rechargeable or
a non-rechargeable SNM system. A study examined which
factors could predict whether a non-rechargeable or recharge-
able system was more appropriate for patients receiving a SCS
system for treatment of chronic pain.15 In this study of subjects
with rechargeable SCS therapy, 20% of subjects reported that
FIGURE 2 Therapy amplitude setting and estimated
neurostimulator recharge interval at 3-month follow-up. A, Distribution
of amplitude settings for all implanted subjects based on active
stimulation settings when the patient departed the 3-month visit
(n= 48). Amplitude setting is programmed using the Clinician
Programmer. B, Distribution of estimated recharge interval for all
implanted subjects based on stimulation settings at 3-month visit
(n= 48). Estimation provided by Axonics Modulation Technologies, Inc
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recharging was not worth the added battery life of a 10-year
rechargeable battery. These patients, compared to subjects
reporting charging was worth the extra battery life, were
significantly older (average of 74 vs 56 years), charged more
frequently (average of 10 vs 5 times per month) and charged
longer (2.4 vs 1.6 h per charge on average).15 However,
selecting a rechargeable or non-rechargeable system for a
patient based on recharge interval or duration is not practical
given recharge interval and recharge duration are not known
until the system is implanted and may change with
reprogramming. Further, recharging 10 times per month for
2.4 h is not consistent with the charging experience of any
subject in this study of rechargeable SNM. The rechargeable
SNMsystem in this study has amore favorable neurostimulator
battery life, with 15-year expected life and, based on this study,
an estimated 2-4 recharges per month, suggesting a profile
consistent with patients reporting recharging was a worthwhile
tradeoff to get extended battery life.
Rechargeable neurostimulation systems have reported
patient complaints related to excess heat generation during
charging,15 however, no adverse events related to charging
were reported in this study. The unique titanium-ceramic
construction of the Axonics neurostimulator (Figure 1) is
designed to provide safer recharging compared to recharge-
able SCS devices. Additionally, the system has temperature
sensors and software controls that pause charging if the
patient's skin temperature increases significantly. These
features suggest the rechargeable SNM system may not incur
the charging related issues of SCS devices, and longer term
follow-up of the subjects in this study will further evaluate
these claims.
The limitation of this study is that specific questions
regarding patient perceptions of recharging, including ease of
use and burden relative to therapy benefit, were not included.
Additionally, estimates of battery life are based on stimula-
tion settings and an algorithm provided by the manufacturer.
Future studies that provide patient reported or diary-based
tracking of charging frequency and duration will provide
valuable insights into the charging experience of patients
using rechargeable sacral neuromodulation systems.
FIGURE 3 Subject satisfaction with r-SNM therapy at 3 months. A, Subject response at 3 months “How satisfied are you with your r-SNM
therapy? (left) Satisfaction for therapy responders—subjects with ≥50% improvement in leaks and/or voids or a return to <8 voids per day (n= 34).
(right) Satisfaction for therapy non-responders (n= 13). B, Subject response at 3 months to the question “How likely are you to recommend r-SNM
therapy to a friend? (left) Likelihood response for therapy responders (n= 34). (right) Likelihood response for therapy non-responders (n= 13)
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The introduction of a rechargeable SNM system is
expected to reduce the need for replacement surgeries due to
battery depletion, resulting in fewer replacement surgeries
and reduced lifetime costs of SNM therapy. The cost-benefit
of rechargeable neuromodulation systems has been modeled
for SNM systems,16 and the rechargeable device reduced was
projected over a 15-year period to reduce therapy costs to the
United States healthcare system by $12 Billion.16 A key
aspect to realizing the cost benefit of rechargeable SNM
therapy is the compliance of subjects with recharging their
systems. The 3-month safety and efficacy results7 and high
rates of therapy satisfaction in this report suggest that, in the
short-term, subjects are not burdened by and are compliant
with recharging their system. Long-term follow-up is
necessary to confirm the benefits of rechargeable SNM
therapy are maintained and to fully assess the cost-savings
associated with rechargeable SNM therapy.
5 | CONCLUSION
The programming settings and estimated recharging intervals
from this clinical study demonstrate that sacral neuro-
modulation with the Axonics r-SNM System is programmed
at similar settings as non-rechargeable SNM and that patients
are able to recharge and are not burdened by recharging
their system. SNM has been shown to be a cost-effective
option for third-line treatment of overactive bladder, and the
cost-effectiveness and appeal of SNM therapy may be
enhanced by the miniaturized, rechargeable SNM system.
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